Oxular

Biotechnology Research • Oxford, England, United Kingdom • 1-10 Employees

Company overview

Headquarters	Magdalen Centre, 1 Robert Robinson Avenue, Oxford, England OX4 4GA, GB
Phone number	+449331313
Websites	oxular.com thrustsc.com
SIC	283
Keywords	Biotechnology, DME, Ophthalmology, Treatment, AMD, Therapeutics, Gene Therapy, Ocular, Retinal Disease, Uveitis, Anti-Vegf, Age-Related Macular Degeneration, Retinoblastoma, Diabetic Macular Edema, Microreservoirs, Oxuflo, Oxulumis, Uveal Melanoma, Retinal Inflammation
Employees	1-10
Socials

Key Contacts at Oxular

Paul Pritchard

Associate Director Of Procurement And Supply Chain

Paul Hawkins

Director Of Information Management

Ian Undefined

Chief Technology Officer

About Oxular

Oxular was acquired by Regeneron in January 2025. To continue following for updated information, please visit Regeneron’s LinkedIn. www.linkedin.com/company/regeneron-pharmaceuticals/ “One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.

Oxular revenue & valuation

Annual revenue	$1,000,000
Revenue per employee	$250,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$3,200,000
Total funding	$37,000,000